EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Long‐term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome

Ingrid E Scheffer iD, Rima Nabbout iD, Lieven Lagae iD, Orrin Devinsky iD, Stéphane Auvin iD, Elizabeth A Thiele iD, Elaine C Wirrell iD, Tilman Polster iD, Nicola Specchio iD, Milka Pringsheim, Katsumi Imai, Michael D Lock iD und 4 weitere

Epilepsia · 2025-06 · 66 (6) · 1919-1932

DOI: 10.1111/epi.18342 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Epilepsia, online erschienen am 12.03.2025. Verfasst von Ingrid E Scheffer und 15 weiteren Autor:innen. Beteiligte Einrichtung: Austin Hospital and Royal Children's Hospital, Florey and Murdoch Children's Research Institutes, University of Melbourne, Melbourne, Victoria, Austr…. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsies, Myoclonic, Fenfluramine. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UCB.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We analyzed the long‐term safety and effectiveness of fenfluramine (FFA) in patients with Dravet syndrome (DS) in an open‐label extension (OLE) study after participating in randomized controlled trials (RCTs) or commencing FFA de novo as adults.

Methods

Patients with DS who participated in one of three RCTs or were 19 to 35 years of age and started FFA de novo were included. Key endpoints were: incidence of treatment‐emergent adverse events (TEAEs) in the safety population, and median percentage change in monthly convulsive seizure frequency (MCSF) from the RCT baseline to end of study (EOS) in the modified intent‐to‐treat (mITT) population. Post hoc analyses compared effectiveness in patients on concomitant stiripentol (STP) vs those not taking STP, and assessed safety (TEAEs) and effectiveness (Clinical Global Impression‐Improvement [CGI‐I] scale ratings) in patients enrolled as adults.

Results

A total of 374 patients, including 45 adults, received ≥1 FFA dose. Median FFA exposure was 824 days (range, 7–1280). TEAEs occurring in ≥10% of patients were pyrexia, nasopharyngitis, decreased appetite, seizure, decreased blood glucose, diarrhea, abnormal echocardiography (only physiologic regurgitation), upper respiratory tract infection, influenza, vomiting, and ear infection; no valvular heart disease or pulmonary arterial hypertension was observed over the OLE. In the mITT population ( n = 324), median percentage change in MCSF from baseline to EOS was −66.8% ( p < .001). The post hoc analyses of MCSF change from baseline to EOS in patients on concomitant STP ( n = 75) was −36.2% vs −71.6% in those not on concomitant STP ( n = 234) ( p < .0001). In adult patients, 29 of 41 (70.7%) and 29 of 42 patients (69.1%) demonstrated clinically meaningful improvement on CGI‐I at last visit as rated by caregivers and investigators, respectively. Significance Our OLE study of FFA in patients with DS confirmed previous positive findings and extended the exposure up to 3.5 years. No new or unexpected safety signals were observed and FFA demonstrated sustained and clinically meaningful reduction in MCSF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsEpilepsies, MyoclonicFenfluramineAdolescentAdultChildFemaleHumansMaleYoung AdultDioxolanesTreatment OutcomeChild, Preschool

Stichwörter der Autor:innen

anti‐seizure medicationepilepsyseizure

Substanzen

AnticonvulsantsDioxolanesFenfluraminestiripentol

Autor:innen und Institutionen

  • Austin Hospital and Royal Children's Hospital, Florey and Murdoch Children's Research Institutes, University of Melbourne, Melbourne, Victoria, Australia.
  • Member of the European Reference Network EpiCARE, Reference Centre for Rare Epilepsies, Necker Enfants Malades Hospital, APHP, Institut Imagine, INSERM U1163, Université Paris Cité, Paris, France.
  • Member of the European Reference Network EpiCARE, University of Leuven, Leuven, Belgium.
  • NYU Langone Medical Center, New York City, New York, USA.
  • Member of the European Reference Network EpiCARE, APHP, Centre de Référence Epilepsies Rares, Hôpital Universitaire Robert-Debré, Paris, France.
  • Université Paris-Cité, INSERM Neuro Diderot, Paris, France.

ORCID-Profile: Ingrid E Scheffer, Rima Nabbout, Lieven Lagae, Orrin Devinsky, Stéphane Auvin, Elizabeth A Thiele, Elaine C Wirrell, Tilman Polster, Nicola Specchio, Michael D Lock, Amélie Lothe

Förderung

  • UCB

Zitieren

APA

Scheffer, I. E., Nabbout, R., Lagae, L., Devinsky, O., Auvin, S., Thiele, E. A., Wirrell, E. C., Polster, T., Specchio, N., Pringsheim, M., Imai, K., Lock, M. D., Langlois, M., Roper, R. Z., Lothe, A., & Sullivan, J. (2025). Long‐term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome. Epilepsia, 66(6), 1919-1932. https://doi.org/10.1111/epi.18342

Vancouver

Scheffer IE, Nabbout R, Lagae L, Devinsky O, Auvin S, Thiele EA, et al. Long‐term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome. Epilepsia. 2025;66(6):1919-1932. doi:10.1111/epi.18342

BibTeX
@article{Scheffer2025,
  author = {Scheffer, Ingrid E and Nabbout, Rima and Lagae, Lieven and Devinsky, Orrin and Auvin, Stéphane and Thiele, Elizabeth A and Wirrell, Elaine C and Polster, Tilman and Specchio, Nicola and Pringsheim, Milka and Imai, Katsumi and Lock, Michael D and Langlois, Mélanie and Roper, Rebecca Zhang and Lothe, Amélie and Sullivan, Joseph},
  title = {Long‐term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome},
  journal = {Epilepsia},
  year = {2025},
  volume = {66},
  number = {6},
  pages = {1919--1932},
  doi = {10.1111/epi.18342}
}
Kostenlos starten →